Agenus

Agenus Gross Margin

The Gross Margin of Agenus (AGEN) as of Oct 15, 2026 is 29.63 %. In the previous year, Gross Margin was -50.79 % — a change of -158.34% (higher).

Gross Margin

29.63 %

YoY

-158.34%

Last updated:

Gross Margin of Agenus is 2025 29.63 % . Gross Margin of Agenus was 2024 -50.79 % . It decreases by -158.34% higher compared to the previous year.

Agenus's gross margin stands at 29.6%, down from 38.4% several years earlier.

The Agenus Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
-238.74 USD
Jan 1, 2019
-12.19 USD
Jan 1, 2020
-64.42 USD
Jan 1, 2021
38.42 USD
Jan 1, 2022
-101.24 USD
Jan 1, 2023
-52.05 USD
Jan 1, 2024
-50.79 USD
Jan 1, 2025
29.63 USD
The Agenus Gross Margin history
YEARGross MarginYoY
29.63 %-158.34%
-50.79 %-2.42%
-52.05 %-48.58%
-101.24 %-363.51%
38.42 %-159.64%
-64.42 %+428.43%
-12.19 %-94.89%
-238.74 %+39.75%
-170.83 %-46.74%
-320.73 %+74.45%
-183.85 %-16.55%
-220.32 %+6,291.83%
-3.45 %-1,264.63%
0.30 %-70.40%
1.00 %+3.80%
0.96 %-3.66%
1.00 %0.00%
1.00 %0.00%
1.00 %0.00%
1.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Agenus Stock analysis

What does Agenus do? Agenus Inc, listed under the ticker AGEN, is a biotechnology company based in Lexington, United States. The company operates within the Health Care sector, specifically in the Biotechnology industry. Agenus Inc has a workforce of 81 employees. It went public through an IPO on February 4, 2000. The company's website is http://agenusbio.com/. Agenus Inc is engaged in the development of technologies aimed at treating cancers and infectious diseases. The company focuses on therapies that harness the immune system to combat cancer. Agenus Inc's activities include the development of antibody discovery platforms, such as Retrocyte Display, SECANT yeast display, and phage display technologies, which are used to create human antibodies. Additionally, the company is involved in the development of vaccine programs, including Prophage, AutoSynVax, and PhosPhoSynVax, as well as saponin-based vaccine adjuvants, notably QS-21 Stimulon. The company's discovery pipeline features checkpoint modulating (CPM) antibodies. Agenus Inc also works with heat shock protein (HSP)-based Prophage vaccine candidates and synthetic vaccine candidates, such as ASV and PSV. The company's headquarters are located in Lexington, Massachusetts, and it maintains a focus on advancing immuno-oncology research and development. Agenus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Agenus stock

Gross Margin of Agenus is 29.63 % in 2025.

Gross Margin of Agenus changed from -50.79 % to 29.63 %, representing a -158.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Agenus since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Agenus with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Agenus

All Key Metrics — Agenus